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Abstract
Background: Although some countries have observed a stabilization in the incidence of CNS, an increasing
incidence has been reported from multiple studies. Recent observations point out to the heterogeneity of
incidence trends according to histological subtypes, gender and age-groups. Using a high-quality regional CNS
tumor registry, this article describes the trends of CNS tumor incidence for main histological subtypes, including
benign and malignant tumors, in the French department of Gironde from 2000 to 2012.
Methods: Crude and age-standardized incidence rates were calculated globally, by histological subtypes, malignant
status, gender and age groups. For trends, annual percent changes (APC) were obtained from a piecewise log-linear
model.
Results: A total of 3515 CNS tumors was registered during the period. The incidence of overall CNS tumors
was 19/100000 person-years (8.3/100000 for neuroepithelial tumors and 7.3/100000 for meningeal tumors). An
increased incidence of overall CNS tumors was observed from 2000 to 2012 (APC = + 2.7%; 95%-confidence interval
(CI): 1.8–3.7). This trend was mainly explained by an increase in the incidence of meningiomas over the period
(APC = + 5.4%, 95%-CI: 3.8–7.0). The increased incidence rate of CNS tumors was more pronounced in female and in
older patients even though the incidence rate increased in all age groups.
Conclusions: Part of the temporal variation may be attributed to improvement in registration, diagnosis and
clinical practices but also to changes in potential risk factors. Thus, etiological studies on CNS tumors are needed to
clarify this rising trend.
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Background
Primary CNS tumors are a complex heterogeneous
group of benign and malignant tumors, with more than
100 histologic subtypes of tumors from the brain to the
spinal cord [1]. Compared to other sites of cancer, CNS
tumors are rare in adults but they represent the second
cause of cancer mortality in individuals aged < 19 years
[2]. Estimating the burden of CNS tumors in the popula-
tion requires considering heterogeneity in the trends ac-
cording to histology, gender and age. From the 1970s to
early 1990s, trends - generally described overall or only
for gliomas - consistently showed an increase in the inci-
dence rate in developed countries [3–9], especially in the
elderly [10–12] and children [13–17]. Although the rea-
son for this increase was debated, one explanation was
that the ability to diagnose CNS tumors improved sig-
nificantly after the introduction of computerized tomog-
raphy scanning in the 1970s and magnetic resonance
imaging in the early 1980s [7, 18]. A better registration
* Correspondence: camille.pouchieu@u-bordeaux.fr
1Equipe EPICENE, Centre INSERM U1219-Bordeaux Population Health Center,
Université de Bordeaux, Bordeaux, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pouchieu et al. BMC Cancer  (2018) 18:653 
https://doi.org/10.1186/s12885-018-4545-9
of non-malignant CNS tumors and an improvement in
clinical practice could have also contributed to this trend
[19, 20]. Since the end of the 1990s, some registries re-
ported continuous increase [4, 9, 21] but others tended
to show that the incidence rate may be levelling off [14,
22] and may even decline [3, 5, 23–25]. Differences in
the observations could also be explained by heterogen-
eity in the types of tumors or characteristics of the pop-
ulations under study [26]. Indeed, recent data confirmed
contrasted patterns of incidence trends for specific types
of tumors and in specific age groups. On the 2000–2010
period in the US, the Central Brain Tumor Registry
(CBTRUS) observed an increase in nonmalignant CNS
tumors [27] since the Benign Brain Tumor Cancer
Registries Amendment Act that made their collection
mandatory [28]. The CBTRUS also observed an increase
in malignant CNS tumors in children and adolescents,
whereas no significant increase was seen in the whole
population [27]. In the specific CNS tumor registry, op-
erated in a French department (Gironde) in 1999, an in-
crease in meningioma incidence rate on the 2000–2007
period was seen (Annual Percent Change (APC) + 5.4%), and
also in neuro-epithelial tumors from 2003 (APC: + 7.5%)
[21]. In the Nordic countries (Denmark, Finland, Norway,
and Sweden), the incidence rate of glioma increased
among those aged 60–79 years from 1974 to 2003,
and after early 1990’s the incidence rate of meningi-
oma increased among female, driven by the 60–
79 year age group [22]. However, the incidence rate
of childhood CNS tumors remained stable during
1985–2006 [29]. The UK cancer registries observed
an increase in the incidence rate of CNS tumors from
1979 to 1992, mainly seen in the young (0–24 years)
and the elderly (65–84 years), with different patterns of
trends for specific types of tumors: meningiomas in-
creased in those 25–84 years of age and pilocytic astrocy-
tomas increased in the 0–24 years age group [10].
The aim of the present study was to provide a de-
scriptive trend analysis of CNS tumor incidence rate
from the Gironde CNS tumor registry, over the




The French network of cancer registries has been previ-
ously described [21]. A cancer registry specifically
collecting data about primary tumors of the CNS is
based in Gironde, a department located in southwestern
France. With an area of 9975 km2, it’s the largest French
department. The population was estimated in 2012 to be
1,483,712 inhabitants (including 257,155 children and
92,327 adolescents). The sex ratio M/F was 0.92 and
about 78% of the population lives in urban area (with a
ratio urban/rural = 3.56). All neurosurgical activity was
based in Bordeaux where the registry is located and no
adjacent department had a neurosurgical institution.
Expertise in pathology was mainly located in the University
Teaching Hospital, which was the regional center of refer-
ence for public and private laboratories. Twenty-nine CT
and 30 MRI machines are now available in the Gironde
area, installed in the 1980s in the largest health centers.
Patients from Gironde with suspected CNS tumors are un-
likely to be referred outside the area, as the regional neuro-
sciences center is based in Bordeaux.
From May 1999, all patients who lived in the depart-
ment of Gironde in whom any new primary tumor of
the CNS was diagnosed, whether symptomatic or
asymptomatic, benign or malignant were prospectively
registered. Spinal tumors were included. We excluded
pituitary tumors, tumors associated with AIDS, recur-
rence of tumors, and metastatic tumors. No case was
obtained from autopsy or from a death certificate only.
Collection of the data is exhaustive because of the col-
laboration of a work group comprising practitioners
(neurosurgeons, neuropathologists, medical oncologists,
radiotherapists, neurologists, etc) involved in the diagno-
sis and therapeutic management of patients. To identify
eligible cases and minimize the number of cases that
may have been missed, multiple overlapping sources
were used: (1) clinical reports obtained through registra-
tion forms filled in by practitioners, (2) extractions from
the French National Hospital Database (PMSI) for relevant
discharge data, (3) neuropatholology reports, (4) requests to
the French Health Insurance Organization (Affections de
Longue Durée) for free health treatment for CNS tumors,
(5) death certificates, and (6) other cancer registries (The
French National Registry of Childhood Solid Tumours and
the Gironde Registry of Hematopoietic Malignancies).
Medical data were individually reviewed to ensure that
the diagnoses were eligible, to check for the diagnosis
date (from April 1999), and to fill in exclusion criteria.
All duplicate cases were thoroughly searched and
excluded. To ensure completeness, a periodic review of
archives and pathology records was performed in the
relevant departments and laboratories. Diagnosis was
based on clinical and radiological data with or without
histological confirmation. Whenever a surgical specimen
was available for neuropathological analysis, the slides
were systematically reviewed by a pathologist not in-
volved in the initial diagnosis. When biopsy or surgical
resection of the tumor was not possible, a monthly as-
sessment was made by experienced neuroradiologists,
neurosurgeons and radiotherapists to ascertain the
diagnosis.
The following parameters were systematically recorded:
date of birth, sex, postal code of usual residence, date of
diagnosis, topography, and tumor histological subtype and
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grade. The usual residence corresponded to the address of
cases at time of initial diagnosis of the tumor.
Classification
Tumors were classified by grouping five-digit histology
codes from the International Classification of Diseases
for Oncology, third edition, into broad histology sub-
groups based on the recommendations from the 2000
Consensus Conference on Brain Tumor Definition for
Registration [30].
Statistical analyses
Overall, age- (five-year age groups) and sex-specific
crude incidence rates (IR) were calculated per 100,000
inhabitants and per year. Population estimates by gender
and calendar year were supplied by the Institut National
de la Statistique et des Etudes Economiques (INSEE)
(http://www.insee.fr/fr/bases-de-donnees/default.asp?pa-
ge=recensement.htm). The study population was divided
into children, adolescents and young adults (0–24 years),
middle aged adults (25–49 years and 50–64 years separ-
ately), and elderly persons (65–80 years and ≥ 80 years
separately). Rates were presented according to the rural/
urban status assigned to the place of usual residence at
time of initial diagnosis, obtained from the INSEE urban
zoning classification (https://www.insee.fr/fr/informa-
tion/2115011). Incidence rates were standardized on the
2000 US Standard Population [31], the Segi World
Standard Population [32] and the Scandinavian “Euro-
pean” Standard Population [33] using the direct method
of analysis to allow comparisons with other cancer regis-
tries. The annual age-standardized incidence rates (per
100,000) were calculated globally and separately for male
and female.
For trends, a piecewise log linear model with constant
variance and uncorrelated errors was run, using Join-
point software (version 3.4.2) available on the Surveil-
lance, Epidemiology and End Results (SEER)*Stat pages
on the US National Cancer Institute website (https://
surveillance.cancer.gov/joinpoint). The method imple-
mented in the software allows choosing the number
and the locations of joinpoints and testing whether an
apparent change in trend is statistically significant. The
test of significance uses a MonteCarlo permutation
method. We considered two jointpoints because the
number of data points was 13. The date of onset was
aggregated into calendar years. We characterized trends
in age and sex-standardized incidence rates using the
French National census 2000–2012 by estimating APCs
with 95% CIs. P < 0.05 was considered statistically sig-
nificant. All tests were two-sided. Here we present data
collected from January 2000 to December 2012.
Results
General characteristics
A total number of 3515 new primary CNS tumors was
registered from 2000 to 2012, among the 1,483,712 in-
habitants of Gironde, corresponding to a crude inci-
dence rate of 19/100000 person-years, which was
unchanged when standardizing on the French popula-
tion (National census). To enable international compari-
sons, age-standardized incidence rates were calculated
using the European Standard Population (Scandinavian,
1960) [33], the 2000 US Standard Population [31] and
the World Standard Population (Segi’s, 1960) [32].
The age-standardized incidence rates of overall CNS
tumors were 17/100000 (Europe), 17/100000 (US),
and 13/100000 (World). Overall, 2706 tumors (77%) were
histologically confirmed (from 63% for meningeal tu-
mors to 89% for neuroepithelial tumors). Regarding
the topography, most of the tumors were supratentor-
ial (38.5%), 35.2% were meningeal, 14.9% were intra-
cranial and intraspinal, 5.5% were unspecified, 4.2%
were infratentorial and 1.7% were ventricular (data
not tabulated).
Incidence by sex, histological subtypes and malignancy
status
The crude and age-standardized incidence rates of CNS
tumors are presented in Table 1 by sex, histological sub-
types and malignancy status. The crude incidence of
CNS tumors was higher in female (21/100000) than in
male (18/100000). Neuroepithelial tumors were the most
frequent histological subtype of CNS tumors in this
registry (n = 1496, 42.6%), followed by meningeal tumors
(37.6%), tumors of the cranial and spinal nerves (12.0%),
other tumors (4.6%) and lymphomas (3.3%). Histological
subtypes are presented in more detail in Table 2. The
most frequent subtypes of neuroepithelial tumors were
glioblastomas (26.9% of CNS tumors) and mixed gliomas
(2.8%). The histological subtypes of CNS tumors differed
by sex: 55.2% of CNS tumors in male were neuroepithe-
lial tumors whereas 49.0% of CNS tumors in female
were meningeal tumors. The distribution and standard-
ized incidence rates by age, sex and histological subtype
are presented in Additional file 1: Table S1. In this CNS
tumor registry, malignant tumors (44%) were less rep-
resented than non-malignant tumors (56%) and this
differed by sex and histological subtypes. Malignant
tumors were more frequent in male (56%) than in fe-
male (35%). Neuroepithelial tumors, cranial and spinal
nerves tumors and lymphomas were mainly malignant
tumors (91%, 99% and 100% respectively) and 98% of
meningeal tumors were non-malignant tumors. Other
tumors that combined different and rare histological
subtypes included 73% of non-malignant tumors (data
not shown).
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Incidence rates by age and sex
Crude incidence rates of CNS tumors are presented by
age and sex in Fig. 1. The incidence rate was 5.5/100000
in children less than 5 years, and ranged from to 3.4 to
5.0/100000 person-years in children aged 5–19 years.
From 20 to 34 years of age, the incidence rate slightly
increased from 5.1 to 9.8/100000. The incidence rate
exceeded 10/100000 after 40 years, 25/100000 after
50, 35/100000 after 55, 45/100000 after 65, and finally
culminated around 50/100000 after 70. Before 40 years
of age, the incidence rate was higher in male than in
female, then the opposite was observed until 80 years.
Histological subtypes by age and sex
The distribution of histological subtypes varied consider-
ably according to age groups and sex (Fig. 2, Additional
file 1: Table S1). In children, adolescents and young adults
(0–24 years), neuroepithelial tumors were the tumors the
most represented (IR = 3.2/100000) with a higher rate in
boys than in girls (3.9 vs 2.5/100000), the incidence rate of
meningeal tumors and tumors of the cranial and spinal
nerves were 0.41/100000 and 0.30/100000, respectively,
both with higher rates in girls than in boys. In this age
group, the incidence rate of other tumors such as cranio-
pharyngiomas, germ cell tumors and unclassified tumors
Table 1 Crude and age-standardized incidence rate of primary CNS tumors according to sex, histological subtype and malignancy
statusa
n % Crude IR/100,000 Standardized IR/100000
Europe US World
Men 1526 18 16 16 13
Malignancy status
Malignant (/3) 860 56 9.9 9.1 9.2 7.3
Non-malignant (/1, /0) 666 44 7.7 7.2 7.2 5.9
Histological subtype
Neuroepithelial tumors 843 55.2 9.7 9.1 9.1 7.3
Meningeal tumors 346 22.7 4.0 3.5 3.7 2.5
Cranial and spinal nerve tumors 208 13.6 2.4 2.3 2.2 1.8
Lymphomas 57 3.7 0.66 0.58 0.58 0.38
Other tumors 72 4.7 0.83 0.77 0.82 0.72
Female 1989 21 17 17 14
Malignancy status
Malignant (/3) 688 35 7.3 5.9 5.9 4.6
Non-malignant (/1, /0) 1301 65 14 12 12 9.1
Histological subtype
Neuroepithelial tumors 653 32.8 6.9 5.8 5.8 4.9
Meningeal tumors 975 49.0 10.4 8.4 8.4 6.5
Cranial and spinal nerve tumors 214 10.8 2.3 2.1 2.0 1.7
Lymphomas 58 2.9 0.62 0.45 0.47 0.35
Other tumors 89 4.5 0.94 0.72 0.77 0.68
All 3515 19 17 17 13
Malignancy status
Malignant (/3) 1548 44 8.6 7.4 7.4 5.9
Non-malignant (/1, /0) 1967 56 11 9.5 9.6 7.6
Histological subtype
Neuroepithelial tumors 1496 42.5 8.3 7.4 7.3 6.1
Meningeal tumors 1321 37.6 7.3 6.1 6.2 4.5
Cranial and spinal nerve tumors 422 12.0 2.3 2.2 2.1 1.8
Lymphomas 115 3.3 0.64 0.51 0.52 0.37
Other tumors 161 4.6 0.89 0.75 0.80 0.70
aPituitary tumors, tumors associated with AIDS, recurrence of tumors, and metastatic tumors were not included in the registry
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was 0.57/100000 and the incidence rate of lymphomas
was 0.04/100000 (0.07 in girls, no tumor registered in
boys). In adults between 25 and 49 years, the incidence
rate of neuroepithelial tumors was 4.4/100000 (5.7 in
men, 3.2 in female) and that of meningeal tumors
was 4.1/100000 (2.1 in men, 6.1 in female). The inci-
dence rate of cranial and spinal nerve tumors was
higher in male than in female (2.7/100000 vs 2.1).
The incidence rates of all other types were less than
1/100000. In 50–64 years, the incidence rate of neuro-
epithelial tumors was similar to that of meningeal tumors
(13.2/ 100,000 and 13.5/100000), the incidence rate of
tumors of the cranial and spinal nerves were higher in
male (5.0/100000) and female (4.5/100000) than in the
previous age group. In persons aged 65–79 years, the
incidence rate of neuroepithelial tumors was 22/100000
(27 in male, 18 in female) and that of meningeal tumors
was 18/100000 (9.9 in male, 24 in female). The incidence
rate of lymphomas was higher than in other age groups
(2.3/100000 in male, 2.4 in female). In subjects aged
80 years and older, meningeal tumors were the most fre-
quent type of CNS tumors (incidence rate = 25/100000)
(26 in female, 21 in male), followed by neuroepithelial
tumors (17/100000) and other tumors (4.3/100000).
Fig. 2 Distribution of main histological subtypes of central nervous system tumors by sex and age, Gironde CNS tumor registry, 2000–2012
Fig. 1 Crude incidence rates of central nervous system tumors by age and sex, Gironde CNS tumor registry, 2000–2012
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Table 3 Annual percent change in age and sex-standardized incidence rates of primary CNS tumors (reference: French National
Census 2000–2012) according to sex, age, histology, malignancy status and urban/rural place of residence, Gironde CNS registry,
2000–2012
n period APC 95% CI, APC Trend P-value
All CNS Tumorsa 3515 2000–2012 + 2.7 (+ 1.8; + 3.7) < 0.0001
Sex
Male 1526 2000–2012 + 1.8 (+ 0.3; + 3.3) 0.006
Female 1989 2000–2012 + 3.6 (+ 2.2; + 5.0) < 0.0001
Age
0–24 y 254 2000–2012 + 0.6 (−2.5; + 3.8) 0.7
25–49 y 730 2000–2012 + 1.2 (− 0.9; + 3.4) 0.2
50–64 y 1088 2000–2012 + 1.2 (− 0.6; + 3.1) 0.2
65–79 y 1000 2000–2012 + 3.0 (+ 0.8; + 5.2) 0.002
80 y and overb 443 2000–2002 + 62 (+ 27; + 108) < 0.0001
2002–2012 + 1.4 (− 2.4; + 5.4) 0.4
Place of residence
Urban 2835 2000–2012 + 2.4 (+ 1.6; + 3.2) < 0.0001
Rural 680 2000–2012 + 4.0 (+ 1.4; + 6.8) 0.0008
Histological confirmation
Yes 2706 2000–2012 + 2.1 (+ 1.1; + 3.2) < 0.0001
No 809 2000–2012 + 4.8 (+ 2.8; + 6.9) < 0.0001
Malignant tumors(/3) 1548 2000–2012 + 1.3 (− 0.20; + 2.8) 0.06
Sex
Male 860 2000–2012 + 0.99 (− 0.82; + 2.8) 0.2
Female 688 2000–2012 + 1.7 (−0.42; + 3.9) 0.1
Age
0–24 y 122 2000–2012 + 0.90 (− 3.5; + 5.5) 0.6
25–49 y 268 2000–2012 − 1.2 (− 5.9; + 3.7) 0.6
50–64 y 457 2000–2012 + 1.4 (− 1.3; + 4.2) 0.2
65–79 y 513 2000–2012 + 1.3 (−1.4; + 4.0) 0.3
80 y and over 188 2000–2012 + 2.0 (−4.0; + 8.4) 0.5
Non-malignant tumors (/1, /0) 1967 2000–2012 + 4.0 (+ 2.7 − + 5.3) < 0.0001
Sex
Male 666 2000–2012 + 3.1 (+ 0.35; + 5.8) 0.01
Female 1301 2000–2012 + 4.6 (+ 2.6; + 6.7) < 0.0001
Age
0–24 y 132 2000–2012 + 0.53 (−3.3; + 4.5) 0.8
25–49 y 462 2000–2012 + 2.8 (+ 0.35; + 5.3) 0.01
50–64 y 631 2000–2012 + 1.3 (−1.3; + 3.9) 0.3
65–79 y 487 2000–2012 + 4.8 (+ 2.3; + 7.4) < 0.0001
80 y and overb 255 2000–2002 + 103 (+ 5.1; + 292) 0.01
2002–2012 + 4.5 (−0.70; + 10) 0.05
Neuroepithelial tumors 1496 2000–2012 + 1.5 (−0.34; + 3.5) 0.1
Sex
Male 843 2000–2012 + 1.5 (−0.64; + 3.6) 0.1
Female 653 2000–2012 + 1.6 (−0.54; + 3.9) 0.1
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Trends over the 13-year period
All CNS tumors
From 2000 to 2012, the APC for overall CNS tumors
was + 2.7% and was statistically significant (p < 0.0001)
(Table 3). The increase of the age-standardized incidence
rates (using the French National Census as reference
population) was higher in female (+ 3.6%, p < 0.0001)
than in male (+ 1.8%, p = 0.006). The IRs in the age
groups younger than 65 years were quite higher during
the period. An increase in incidence rate was observed
in all age groups (Fig. 3a), but significant only in the 65
to 79-year-old age group on the whole period (+ 3.0%,
p = 0.002). The changes in the rates over the period
did not appear to be related to the usual place of
residence at the time of diagnosis, as the APC was similar
in urban (+ 2.4%) and rural (+ 4.0%) settings, nor to the
rate of histological confirmation, as the annual increase
was observed in tumors both with (+ 2.1%, p < 0.0001) and
without (+ 4.8%, p < 0.0001) histological confirmation.
According to malignancy status and histological subtypes
No time trend was found for malignant CNS tumor but an
increase in non-malignant tumors was observed (+ 4.0%),
slightly higher in female (+ 4.6%, p < 0.0001) than in male
(+ 3.1%, p= 0.01) and specifically in patients aged 65–79 years
(+ 4.8, p < 0.0001).
A non-significant increase was found for neuroepi-
thelial tumors (+ 1.5%) (Fig. 3), similar in both sexes
(+ 1.5% in men, + 1.6% in female), observed in all age
groups (except the 25–49 years), and slightly more
pronounced in individuals 80 years and over (APC: +
3.7, p = 0.15). A more pronounced increase was
observed for meningeal tumors, with an APC of +
5.4% for the whole period, which was statistically
significant (p < 0.0001). This trend was slightly higher
in male (+ 6.1%, p = 0.01) than in female (+ 5.6%,
p < 0.0001), existed for all age groups except those
50–64 years old but tended to be higher in elderly:
the APC was + 4.2% in the 25 to 49 year old group, +
5.8 in the 65 to 79 year age group and reached + 11%
in the group 80 years and older (p = 0.007, p < 0.0001,
p < 0.0001 respectively). No time trend was found for
cranial and spinal nerve tumors and unstable results
were obtained for lymphomas and other tumors
owing to the limited number of cases over the 13 years
period.
Table 3 Annual percent change in age and sex-standardized incidence rates of primary CNS tumors (reference: French National
Census 2000–2012) according to sex, age, histology, malignancy status and urban/rural place of residence, Gironde CNS registry,
2000–2012 (Continued)
n period APC 95% CI, APC Trend P-value
Age
0–24 y 179 2000–2012 + 1.3 (−3.8; + 6.6) 0.6
25–49 y 278 2000–2012 −1.1 (−5.9; + 4.0) 0.6
50–64 y 430 2000–2012 + 1.6 (−0.95; + 4.2) 0.2
65–79 y 458 2000–2012 + 1.5 (−1.5; + 4.6) 0.3
80 y and over 151 2000–2012 + 3.7 (−1.9; + 9.7) 0.1
Meningeal tumors 1321 2000–2012 + 5.4 (+ 3.8; + 7.0) < 0.0001
Sex
Male 346 2000–2012 + 6.1 (+ 0.82; + 11) 0.01
Female 975 2000–2012 + 5.6 (+ 3.4; + 7.8) < 0.0001
Age
0–24 y 24 2000–2012
25–49 y 258 2000–2012 + 4.2 (+ 0.75; + 7.8) 0.007
50–64 y 445 2000–2012 + 1.5 (−1.1; + 4.2) 0.2
65–79 y 375 2000–2012 + 5.8 (+ 2.5; + 9.2) < 0.0001
80 y and over 219 2000–2012 + 11 (+ 5.1; + 17) < 0.0001
Other histological subtypes
Cranial and spinal nerve tumors 422 2000–2012 + 0.68 (−0.75; + 2.1) 0.3
Lymphomas 115 2000–2012 + 3.6 (−3.5; + 11) 0.3
Other tumorsc 161 2000–2012 − 1.2 (−6.6; + 4.5) 0.6
CI confidence interval, APC annual percent change
aPituitary tumors, tumors associated with AIDS, recurrence of tumors, and metastatic tumors were not included in the registry
bThe joinpoint analysis identified two trends for individuals 80 years and over: 2000–2002 and 2002–2012
cOther tumors included germ cell tumors, tumors of the sellar region and unclassified tumors
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Discussion
The Gironde CNS Tumor Registry that reports all histo-
logical subtypes, including benign and malignant tu-
mors, provides reliable data on CNS tumor incidence
rate in the southwestern area of France with the longest
period of follow-up available for specific types of tumors
such as meningioma. The incidence rate of overall CNS
tumors was 19/100000 person-years on the period
2000–2012 and the age-standardized rates were 17, 17
and 13/100000 using the European Standard Population
(Scandinavian 1960), the 2000 US Standard Population
and the World Standard Population (Segi, 1960),
respectively, which was higher than observed in other
cancer registries [9, 23, 34–41]. The distribution of age
groups was quite similar between the US and the
European standard populations explaining similar rates.
However, the lowest rate was observed standardizing on
the World Standard Population since this population was
younger than other standards (40% was aged < 20 years
and 11% was aged ≥60 years in the World standard vs
29% and 16% in others standards). Large geographical and
temporal variations have been observed in the incidence
rate of CNS tumors ranging from 5.9 to 21/100000 ac-
cording to cancer registries, due to the limitations and
heterogeneity of registration procedures. However, few
data has been published over a comparable period and
mainly focused on malignant CNS tumors, which makes
comparisons difficult. For malignant tumors, the CBTRUS
found a 8.9/100000 incidence rate standardized on the
2000 US standard population [27] and the New Zealand
Cancer Registry observed a 6.7/100000 incidence rate
standardized on the WHO standard population [25],
which were comparable to the rates we found in Gironde
when focusing on malignant CNS tumors (7.4/100000
when standardized on the 2000 US standard population).
The most comparable data derived from the Austrian Brain
Tumor Registry, which found an age-standardized inci-
dence rate (US) of 18/100000, corresponding to 16/100000
when excluding tumors of the sellar region [34]. Concern-
ing meningioma, the incidence rate standardized on the
2000 US standard population was slightly lower to that
found by the SEER Program (6.2 in Gironde vs 7.6/100000
in the US) [42].
The global characteristics of CNS tumors included in
the Gironde Tumor Registry were consistent with most
other studies [9, 26, 43, 44]. The incidence rate of overall
CNS tumors increased dramatically with age, neuroepi-
thelial tumors were the histological subtype the most
represented in male whereas meningeal tumors were the
most represented in female.
From 2000 to 2012, we observed an increase in the in-
cidence rate of CNS tumors (APC = 2.7%), which was
explained mainly by an increase in the incidence rate of
meningioma over the period (APC = + 5.4%). The overall
increase in the incidence rate of CNS tumors was more
pronounced in female and in elderly persons. Other
authors have found an overall increase in CNS tumors,
especially in older ages even if they did not detect clear
changes in specific subgroups [9, 10, 22, 39]. In the eld-
erly, the overall increase may be attributed to the in-
crease of meningioma incidence rate over the entire
period (+ 11%, p < 0.0001). We can notice that this rising
trend in meningioma is outstanding compared to other
publications, which may be partly explained by the
willingness of clinicians to pursue a diagnosis in older
patients. This result is in line with the finding that the
incidence rate of meningioma increased 3.9-fold from
1943 to 1997 in Denmark [45]. Arora observed that the
incidence rate of meningioma significantly increased in
England for the period 1979–2003 with the highest in-
creases in those 65–84 years (+ 2.9%) [10]. Dolecek has
also found a 3.8 increase in benign meningioma in
Fig. 3 a Trends in age-specific incidence rate of central nervous system tumors, Gironde CNS tumor registry, 2000–2012. b Trends in crude
incidence rate of central nervous system tumors by histological subtype, Gironde CNS tumor registry, 2000–2012
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elderly persons ≥75 years in the United States from 2004
to 2011 [42].
The temporal trend we observed may have several ex-
planations: improvement in tumor registration, diagnosis
and clinical practice although no significant change in
the registration procedure or in access to imagery tech-
nologies was observed during this period. The indication
of surgical procedures has changed over time. As more
patients undergo surgery, the number of histological
confirmation increases. However, this should have a
minimal impact in our study as there was an increased
incidence rate in tumors both with and without histo-
logical confirmation, which was twice as higher for
tumors without histological confirmation (APC = + 2.1
and + 4.8, respectively). However, we cannot rule out
that the use of three new sources of tumor registration
from 2005 to 2007 may contribute to this rising trend al-
though this is unlikely to explain the difference between
sex and histological subtypes.
Even if the role of environmental risk factors (pesti-
cides, electromagnetic fields) was not well-established,
changes in potential risk factors may also be responsible
for this temporal trend. With about 135,000 ha of vine-
yards and 28,000 individuals involved in wine-growing
in the department, it cannot be excluded that these find-
ings may be explained by environmental risk factors,
notably by the potential role of pesticides that are largely
used in vineyards. Indeed, a case-control study conducted
in Gironde found that a high level of occupational expos-
ure to pesticides might be associated with an excess risk
of brain tumors, especially of gliomas [46]. The last
20 years, the prevalence of obesity in France have been in-
creasing steadily, including in the South-West area [47].
Recently, a meta-analysis of 12 cohorts and case-control
studies found that overweight and obesity have been asso-
ciated with increased risk of meningiomas [48]. Thus, we
cannot exclude that the body mass index may partly con-
tribute to the increasing trend in meningioma incidence
rate. In addition, mobile phones were introduced in the
1980’s and became widespread by the early 1990s. There
is growing concern that the exposure to mobile phone use
might increase the risk of CNS tumors. In 2013, the
International Agency for Research on Cancer (IARC) clas-
sified radiofrequencies generated by mobile phones as
possible human carcinogens on the basis of epidemio-
logical data that showed an increased risk of gliomas [49].
The predominance of meningioma for female also sug-
gests a potential role of hormonal factors. Indeed, higher
incidence rate of meningioma has been observed in female
of reproductive age, in tumor expression of hormone re-
ceptors, and changes in the size of meningioma during
pregnancy, the menstrual cycle and menopause [50].
However, apart from ionizing radiation that has been clas-
sified as an agent with sufficient evidence of
carcinogenicity in humans for cancers of the brain and
CNS (Group 1) by the IARC [51], the role of these factors
remain unresolved and further investigation is needed.
Conclusions
Although the incidence rate of CNS tumors has tended
to level off in some countries, we highlighted an overall
increase in CNS tumor incidence rate in the French de-
partment of Gironde, during a recent 13 years period
(2000–2012), especially for meningiomas. The present
analysis also pointed at several patterns of incidence
trends for CNS tumors, according to histological sub-
types, sex and age groups, suggesting potential changes
in lifestyle, environmental or occupational risk factors of
CNS tumors. The increase in meningioma over the
period was in line with recent findings from other
studies. Consistently, the overall increase was more
pronounced in female and in elderly persons but the rea-
sons for the trends remain unclear. Thus, etiological
studies which aims at elucidating the potential role of
environmental and occupational exposures (including
pesticides and electromagnetic fields) on brain tumors
are needed to clarify this rising trend.
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